Baxter International Inc. with ticker code (BAX) now have 12 market analysts covering the stock. The analyst consensus now points to a rating of ‘hold’. The target price High/Low ranges between 56 and 41 with the average target price sitting at $49.83. Now with the previous closing price of $37.32 and the analysts are correct then we can expect a percentage increase in value of 33.5%. The 50 day MA is $39.89 and the 200 day MA is $42.78. The market cap for the company is 16.58B. The stock price for the company is currently is currently 32.74 USD
The potential market cap would be $22,137,365,693 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 30.03 and a 3.7% return on assets.
Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s segments include Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia-Pacific), and Hillrom. The Americas, EMEA and APAC segments provide a portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals, and surgical hemostat and sealant products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.
